Neurocrine stock rockets to a record on sales beat—but can it last?
November 03, 2017 at 06:59 AM EDT
Neurocrine charged many patients twice the price of the drug in the latest quarter—but it is coming to an end.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|